Exploring High-Dose Inhaled Nitric Oxide as an Antimicrobial Agent: Opportunities, Risks, and Future Directions

Category	Detail
Condition	High-Dose Inhaled Nitric Oxide (iNO) as an Antimicrobial Agent
Key Mechanisms	Reactive nitrogen species chemistry, biofilm-disrupting effects, immune modulation
Target Population	Patients with lower respiratory infections, including severe viral pneumonia and multidrug-resistant bacterial infections
Care Setting	Critical care and respiratory medicine

High-dose iNO is being explored for bacterial pneumonia, viral respiratory infections, and chronic nontuberculous mycobacterial disease.
The study showed transient methemoglobin elevations exceeding 10% in some subjects during exercise.
Previous use of iNO in ARDS did not show mortality benefits and increased acute kidney injury risk.
Ongoing trials are examining iNO in pneumonia populations directly.
Careful monitoring for toxicity is essential as investigations proceed.

Monitor methemoglobin levels and nitrogen dioxide exposure during iNO administration.

Consider high-dose iNO for severe respiratory infections pending further evidence.

Implement confirmatory blood CO-oximetry and monitor for transient methemoglobinemia.

Healthy volunteers in initial studies; future studies needed for patients with respiratory illness.

Intermittent high-dose iNO administration has shown feasibility with mostly mild adverse events.

Define safe exposure thresholds and optimal dosing for antimicrobial effects.
Specify ventilator-compatible delivery systems in future studies.
Ensure accurate detection of adverse events through robust monitoring strategies.